肿瘤科（内科）

以下为当前的临床试验。

按位置、状态和其他条件筛选该研究列表。

1. A Study To Evaluate Hyperthermic Intraperitoneal Chemotherapy To Treat Patients With Pancreatic Cancer And Peritoneal Metastasis

   Rochester, Minn.

   The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy.

    

    

2. Turkey Tail Mushroom For Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

   Scottsdale/Phoenix, Ariz.

   This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

3. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

4. A Study Of Biomarkers To Predict Cancer Therapy-related Cardiotoxicity

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The primary purpose of this study is to collect Biospecimens from patients who developed chemotherapy related cardiac toxicity (CRCT) and patients who are at a high risk for developing CRCT identified prior to the onset of therapy.

5. Changes In Blood Components In Patients With Ovarian Cancer

   Rochester, Minn.

   The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer for future research projects to identify changes in levels of various plasma components that occur during the course of ovarian cancer, including changes that occur with debulking surgery, chemotherapy, disease relapse, and subsequent therapy.

6. (Z)-Endoxifen For The Treatment Of Premenopausal Women With ER+/HER2- Breast Cancer

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part.
   
   The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules daily. Twelve participants will be randomly assigned (50/50 chance) to take (Z)-endoxifen alone or (Z)-endoxifen with a monthly injection of goserelin a drug that temporarily stops the ovaries from making estrogen. This part will help determine the best dose of (Z)-endoxifen by measuring the drug levels in the blood and how long the body takes to remove it.
   
   The Treatment Cohort has been simplified to a single study arm (Z)-endoxifen + goserelin. Up to 20 participants will be enrolled that have a baseline Ki-67 ≤ 10% and 45 participants will be enrolled that have a baseline Ki-67\>10%.
   
   A key goal of the study is to see if (Z)-endoxifen can slow down or stop tumor growth as measured by a reduction in Ki-67 levels. Tumor tissue samples will be taken by breast biopsy after about 4 weeks of treatment to check levels of this biomarker. If the tumor shows signs of response, participants can continue treatment for up to 24 weeks or until they have surgery.
   
   Study participation is up to 6 months (24 weeks of treatment) followed by surgery and a one-month follow up visit.

7. International Hepatobiliary Neoplasia Registry and Biorepository

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   This study is being done to:

   1. Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or gallbladder cancer, and those individuals who have normal risk factors in order to improve the ability to diagnose and treat these cancers. We will use information in the medical record in this registry including how far advanced the cancer is (stage) and what treatments are used to treat the cancer.

   2. A second purpose of this study is to obtain blood and tissue samples from participants having or at risk for developing cancer of the liver or bile ducts or gallbladder cancer to be used for future research testing. Future testing may include searching for changes in the genetic material (DNA and other molecules).

8. Gastrointestinal-Related Cancers and Diseases

   Rochester, Minn.

   The purpose of applying to the Institutional Review Board (IRB) for the collection of GI-related tissue is to enable comprehensive molecular investigations into the mechanisms underlying gastrointestinal cancers and diseases.

9. Onvansertib For The Treatment Of Recurrent Or Refractory Chronic Myelomonocytic Leukemia

   Rochester, Minn.

   This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death.

10. Extracellular Impact Of Ultrasound-induced Blood-brain Barrier Disruption

    Rochester, Minn.

    The purpose of this study is to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment.